Published in final edited form as:

J Org Chem. 2009 August 7; 74(15): 5730–5733. doi:10.1021/jo900861x.

Syntheses of Carbocyclic Uracil Polyoxin C Analogs: Application of Pd(0)/InI-Allylation of 4-Acetoxy-2-azetidinone

Cara Cesario and Marvin J. Miller*

Department of Chemistry and Biochemistry, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, Indiana 46556

Abstract

Carbocyclic uracil polyoxin C analogs are synthesized in less than nine steps from an acylnitroso-derived hetero Diels–Alder adduct. Pd(0)/InI-mediated allylation of 4-acetoxy-2-azetidinone is used to install the β -amino acid side chain at the C-5' position of the carbocycle.

Polyoxins and nikkomycins are peptidyl nucleoside natural products that selectively target fungi while remaining nontoxic to plants, animals and bacteria.¹ Specifically, these molecules are inhibitors of chitin synthase,² an enzyme responsible for the synthesis of the fungal cell wall component chitin. Disrupting chitin biosynthesis compromises the structural integrity of fungal cell walls and results in death of the pathogen.³ Because plant and mammalian cells do not produce chitin, inhibition of chitin synthase only affects fungal cells and is considered a potentially safe and nontoxic approach toward combating fungal infections.

Although polyoxins and nikkomycins demonstrate competitive inhibition of chitin synthase in enzyme assays,⁴ the ionized amino acid side chain significantly impedes their cellular transport and has precluded their development as fungicidal agents. Additionally, polyoxins and nikkomycins are less effective in vivo due to their instability toward intracellular proteases.⁵ In efforts to prepare polyoxin and nikkomycin derivatives with increased potency, several analogs have been synthesized with diverse amino acid side chains,⁶ inverted configurations⁷ and different nucleoside bases.⁸

Additionally, prodrug variants of polyoxins and nikkomycins have been designed to permeate fungal cell membranes and release the active component upon intracellular hydrolysis.⁹ Despite extensive modification of the peptidyl subunits, less effort has focused on structural changes at the central ribose core. By replacing the furanose oxygen with a methylene unit, several classes of carbocyclic nucleosides have displayed increased metabolic stability and improved biological activity.¹⁰ To date, syntheses of carbocyclic derivatives of polyoxins and nikkomycins have been limited.¹¹ Herein, we disclose the synthesis of carbocyclic uracil polyoxin C analogs **1a** and **2a** as potential antifungal agents (Chart 1).

Recently, we reported the diastereoselective allylation of 4-acetoxy-2-azetidinone from a unique allylindium precursor, acylnitroso-derived hetero-Diels-Alder adduct **3**, to incorporate highly functionalized cyclopentenones at the azetidinone C-4 position.¹² Further elaboration of synthon **4** would reveal an unprecedented polyoxin C analog bearing an azetidinone at the C-5' position. Interestingly, several naturally occurring polyoxins (i.e. Polyoxin I)¹³ contain 2-carboxyazetidine side chains and illustrate the structural diversity in this class of molecules. The protected β -amino acid side chain renders polyoxin C analog **1a** as having the potential for improved antifungal activity due to its neutral character. Furthermore, intracellular hydrolysis of target molecule **1a** would provide compound **2a** and reveal the free amino and carboxy groups, two functionalities that are required for inhibition.¹⁴

In a first attempt to synthesize key intermediate **8**, *N*-hydroxycarbamate **4** was reduced to carbamate **5** in the presence of titanocene (III) monochloride¹⁵ generated in situ (Scheme 1). Treatment of compound **5** with TFA and anisole in refluxing CH₂Cl₂ formed the amine salt in quantitative yield after 3 h. The crude material was treated with acyl isocyanate **6**¹⁶ freshly dissolved in benzene. The reaction was complete within 18 h to afford acyl urea **7** in 47% yield. Cyclization of compound **7** to uracil **8** proved problematic. Starting material **7** was unreactive towards ZnCl₂ and *p*-toluene sulfonic acid at 60 °C. Strong acidic conditions (i.e. 1M H₂SO₄ or TFA) or strong basic conditions (i.e. NH₄OH) opened the azetidinone ring. The desired product **8** was never observed.

We recognized that the *N*-protio β -lactam required protection to survive cyclization to uracil **8**. As the azetidinone ring of compound **7** is susceptible to opening in the presence of strong acid or base, we required a protecting group that could be installed and removed under neutral conditions. Our group has previously reported *N*-sulfenylation of 2-azetidinones with *N*-methylthiophthalimide.¹⁷ Additionally, the *N*-methylthio group is easily removed under neutral conditions with 2-mercaptopyridine.¹⁸ Accordingly, compound **5** was refluxed in CH₂Cl₂ with *N*-methylthiophthalimide **9**¹⁹ to afford protected azetidinone **10** in 88% isolated yield²⁰ (Scheme 2). *N*-Methylthio- β -lactam **10** was refluxed in the presence of TFA and anisole to remove the Boc group. The resultant crude material was treated with a freshly prepared benzene solution of acyl isocyanate **6** to provide acyl urea **11** in an improved 77% yield. With the *N*-methylthio group installed in compound **11**, cyclization to the uracil base readily occurred in 1M H₂SO₄ and CH₃CN at 80 °C to afford desired product **12**. Removal of the *N*-methylthio group was achieved with 2-mercaptopyridine to afford key carbocycle **8**.

Although we developed an optimized route to intermediate **8**, we anticipated low diastereoselectivity for **1a** in the subsequent dihydroxylation reaction.²¹ As predicted, a 1:3 mixture of *cis*-diols **1a** and **1b**, respectively, was obtained after OsO₄-catalyzed dihydroxylation of cyclopentene **8** (Scheme 3). In an effort to increase the ratio of **1a**, we investigated Woodward-Prévost conditions²² as an alternative method to install the *cis*-diol from the same face as the allylic methine protons in cyclopentene **8**.²³ Although the Woodward-Prévost method has previously been used in the synthesis of carbocyclic nucleosides,²⁴ the strong oxidizing conditions (i.e. I₂ and AgOAc) were not compatible with **8**, yielding a complex product mixture.

Finally, a mixture of *cis*-diols **1a** and **1b** was treated with an aqueous solution of NaOH to afford carbocyclic homo-uracil polyoxin C analogs **2a** and **2b**, respectively.

In summary, Pd(0)/InI-mediated allylation chemistry has been applied in the syntheses of azetidinone-derived and carboxylic acid-related carbocyclic nucleosides **1a** and **1b** and β -amino acid related-carbocyclic nucleosides **2a** and **2b**. We are currently screening final compounds **1a-b** and **2a-b** as well as relevant intermediates **4**, **5**, **8**, **10** and **12** for anti-cancer,

antimicrobial, antiviral and antifungal activity. Detailed biological studies will be described subsequently.

Experimental Section

(±)-*tert*-Butyl-(1*R**,4*S**)-4-((*S**)-4-oxoazetidin-2-yl)cyclopent-2-enylcarbamate **5**

A clean flame-dried 250 mL round bottom flask was evacuated and purged with Ar. A THF solution (50 mL) of Cp_2TiCl_2 (2.55 g, 10.2 mmol) and activated zinc (1.34 g, 20.5 mmol) was stirred at rt under Ar for 45 min. The reaction mixture changed color from dark red to olive green. The reaction mixture was cooled to -30°C and treated dropwise over 3 min with a MeOH solution (40 mL) of compound **4** (1.1 g, 4.1 mmol). The reaction mixture was stirred for 45 min and while maintaining the bath temperature between -10°C and -30°C . The reaction mixture was warmed to rt and partitioned between sat. K_2CO_3 (10 mL) and EtOAc (40 mL). The organic layer was removed via pipet and filtered through Whatman Glass Microfiber Filter (Type GF/F) (to remove insoluble titanium salts). The aqueous layer was extracted with EtOAc (4×40 mL) and the organic layer was filtered through Whatman Glass Microfiber Filter (Type GF/F) after each extraction. The combined organic layers were dried over MgSO_4 , again filtered through Whatman Glass Microfiber Filter (Type GF/F), and the filtrate was adsorbed on silica gel. The adsorbed material was purified by silica gel chromatography (2% MeOH/ CH_2Cl_2) to afford **5** as an off white foam (747 mg, 72%). An analytical sample was recrystallized from EtOAc to provide a white powder from which all analytical data was obtained. mp $132\text{--}133^\circ\text{C}$; ^1H NMR (600 MHz, CD_3OD) δ 1.27 (1H, ddd, $J = 13.4$ Hz, 6.5 Hz, 6.5 Hz), 1.44 (s, 9H), 2.49 (ddd, 1H, $J = 13.4$ Hz, 8.2 Hz, 8.2 Hz), 2.61 (dd, 1H, $J = 15.0$ Hz, 2.3 Hz), 2.85–2.89 (m, 1H), 2.94 (dd, 1H, $J = 15.0$ Hz, 5.0 Hz), 3.61 (ddd, 1H, $J = 6.2$ Hz, 5.0 Hz, 2.4 Hz), 4.60–4.65 (m, 1H), 5.76–5.80 (m, 2H); ^{13}C NMR (150 MHz, CD_3OD) δ 28.9, 34.8, 48.7, 49.8, 51.8, 57.8, 80.2, 133.7, 136.6, 158.0, 171.1; IR (thin film, cm^{-1}) 3296, 2978, 2931, 1748, 1694, 1520, 1367; HRMS (FAB) m/z $[\text{M}+\text{H}]^+$: calcd for $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_3^+$, 253.1552; found, 253.1570.

3-Methoxy-2-propenoyl isocyanate **6**¹⁶

A clean flame-dried 100 mL round bottom flask equipped with a stir bar and condenser was evacuated and purged with Ar. Silver cyanate (3.02 g, 20.2 mmol) was added to the flask and was heated to 50°C (bath temperature) under vacuum for 18 h and then heated to 100°C (bath temperature) for 2 h while the acid chloride was prepared. A clean flame-dried 50 mL round bottom flask equipped with a stir bar, 4Å molecular sieves and a condenser was evacuated and purged with Ar. A CH_2Cl_2 (16 mL) suspension of sodium-3-methoxy-2-propenoate (1.0 g, 8.06 mmol) was cooled to 0°C and treated with oxalyl chloride (0.82 mL, 9.67 mmol) followed by DMF (0.06 mL, 0.81 mmol) and the reaction mixture was refluxed for 2 h. The reaction mixture was then cooled to rt and filtered through a glass fritted funnel. The filtrate was transferred to a 50 mL round bottom flask (previously flamed dried and purged with Ar), concentrated *in vacuo* to yellow solids and the flask was back-filled with Ar. Meanwhile, dry benzene (20 mL) was added to the heated flask containing silver cyanate and the solution was refluxed for 30 min. A benzene solution (20 mL) of the acid chloride was added dropwise to the refluxing solution of silver cyanate. The reaction mixture was refluxed for 1.5 h and then cooled to rt. The solids were filtered through Whatman Glass Microfiber Filter (Type GF/F) and the filtrate was used directly in the preparation of **7** or **11**.

(±)-(*E*)-3-Methoxy-*N*-((1*R**,4*S**)-4-((*S**)-4-oxoazetidin-2-yl)cyclopent-2-enylcarbamoyl)acrylamide **7**

A clean flame-dried 10 mL round bottom flask equipped with a stir bar and condenser was evacuated and purged with Ar. A CH_2Cl_2 (2 mL) solution of compound **5** (100 mg, 0.40 mmol) was treated with anisole (0.047 mL, 0.44 mmol) and then TFA (0.15 mL, 1.99 mmol). The

reaction mixture was refluxed for 3 h at 60 °C (bath temperature). The reaction mixture was concentrated to a brown oil, toluene (1 mL) was added, and the solution was concentrated to an oil. CH₂Cl₂ (2 mL) was added to the resultant residue. The solution was cooled to 0 °C and then treated with DIPEA (0.69 mL, 3.96 mmol). The reaction mixture was stirred for 5 min under Ar at 0 °C and was then treated with a benzene solution of 3-methoxy-2-propenoyl isocyanate **6** (100 mg, 0.80 mmol, assuming quantitative yield from the previous step). The reaction was stirred for 15 h under Ar as the temperature warmed to rt overnight. The reaction mixture was concentrated to a tan oil and partitioned between CH₂Cl₂ (3 mL) and 10% citric acid (2 mL). The aqueous layer was extracted with CH₂Cl₂ (4 × 3 mL). The combined organic layers were washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated to a tan oil. The residue was purified by silica gel chromatography (100% EtOAc) to afford **7** as a yellow gum (52 mg, 47%). ¹H NMR (600 MHz, CDCl₃) δ 1.41 (ddd, 1H, *J* = 13.5 Hz, 5.9 Hz, 5.9 Hz), 2.56 (ddd, 1H, *J* = 13.5 Hz, 8.2 Hz, 8.2 Hz), 2.65 (ddd, 1H, *J* = 14.7 Hz, 2.6 Hz, 1.2 Hz), 2.91–2.95 (m, 1H), 3.02 (ddd, 1H, *J* = 15.0 Hz, 2.6 Hz, 1.2 Hz), 3.67 (ddd, 1H, *J* = 5.3 Hz, 5.3 Hz, 2.3 Hz), 3.74 (s, 3H), 4.92–4.97 (m, 1H), 5.20 (d, 1H, *J* = 12.3 Hz), 5.81 (ddd, H, *J* = 5.6 Hz, 3.8 Hz, 2.1 Hz), 5.88 (ddd, 1H, *J* = 5.6 Hz, 4.4 Hz, 2.1 Hz), 5.90 (bs, 1H), 7.66 (d, 1H, *J* = 12.3 Hz), 8.00 (bs, 1H), 8.61 (bd, 1H, *J* = 8.2 Hz); ¹³C NMR (150 MHz, CDCl₃) δ 33.9, 41.8, 48.9, 50.9, 55.9, 58.5, 97.6, 133.6, 134.6, 153.7, 164.5, 167.8, 167.9; IR (thin film, cm⁻¹) 3258, 2921, 1737, 1678, 1614, 1538; HRMS (FAB) *m/z* [M+H]⁺: calcd for C₁₃H₁₈N₃O₄⁺, 280.1297; found, 280.1303.

(±)-1-((1*R,4*S**)-4-((*S**)-4-Oxoazetidin-2-yl)cyclopent-2-enyl)pyrimidine-2,4(1*H*,3*H*)-dione **8****

A CH₂Cl₂ solution (10 mL) of **12** (0.56 g, 1.91 mmol) and 2-mercaptopyridine (0.26 g, 2.29 mmol) in a pressure tube was treated with Et₃N (0.32 mL, 2.29 mmol). The tube was sealed with a teflon screw cap and the heterogeneous reaction mixture was stirred for 18 h at 60 °C (bath temperature). The reaction mixture was cooled to 0 °C and the precipitate was filtered and washed with hexanes to afford **8** as an off-white solid (0.40 g, 84%). mp 246–247 °C (dec); ¹H NMR (600 MHz, DMSO-*d*₆) δ 1.21 (ddd, 1H, *J* = 13.8 Hz, 6.8 Hz, 6.8 Hz), 2.50–2.56 (m, 2H), 2.85 (dd, 1H, *J* = 5.0 Hz, 2.1 Hz), 2.86–2.90 (m, 1H), 3.57 (ddd, 1H, *J* = 8.5 Hz, 2.6 Hz, 2.6 Hz), 5.46–5.50 (m, 1H), 5.57 (d, 1H, *J* = 8.2 Hz), 5.78 (ddd, 1H, *J* = 5.6 Hz, 2.1 Hz, 2.1 Hz), 6.01 (ddd, 1H, *J* = 5.6 Hz, 2.1 Hz, 2.1 Hz), 7.42 (d, 1H, *J* = 7.9 Hz), 7.97 (s, 1H), 11.27 (s, 1H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 32.2, 40.9, 48.4, 48.8, 60.8, 101.6, 131.0, 137.1, 141.7, 150.9, 163.3, 167.0; IR (thin film, cm⁻¹) 1749, 1689, 1614, 1461; HRMS (FAB) *m/z* [M+H]⁺: calcd for C₁₂H₁₄N₃O₃⁺, 248.1035; found, 248.1026.

(±)-1-((1*R,2*S**,3*R**,4*R**)-2,3-Dihydroxy-4-((*S**)-4-oxoazetidin-2-yl)cyclopentyl)pyrimidine-2,4(1*H*,3*H*)-dione **1a** and 1-((1*R**,2*R**,3*S**,4*R**)-2,3-dihydroxy-4-((*S**)-4-oxoazetidin-2-yl)cyclopentyl)pyrimidine-2,4(1*H*,3*H*)-dione **1b****

A *t*-BuOH:H₂O solution (9:1, 1.8 mL: 0.2 mL) of **8** (50 mg, 0.20 mmol) and *N*-methylmorpholine *N*-oxide (47 mg, 0.40 mol) was treated with a 2.5% (w/w) solution of osmium tetroxide in *t*-BuOH (0.40 mL, 0.04 mmol) and the heterogeneous reaction mixture was stirred at rt for 18 h. After 18 h, the clear yellow reaction mixture was treated with solid Na₂S₂O₅ (576 mg, 3.03 mmol) and the mixture was stirred at rt for 30 min. The clear solution was filtered through a Whatman Glass Microfiber Filter (Type GF/F) to remove the brown precipitate. The clear filtrate was concentrated to solids under reduced pressure, toluene (3 mL) was added, and the solution was concentrated to solids. The solids were triturated with MeOH (3 × 5 mL) and the wet solids were dried under vacuum to afford a 1:8 ratio of **1a**:**1b** as white solids (45 mg, 80%). ¹H NMR of the crude reaction mixture indicated a 1:3 ratio of **1a**:**1b**. Compound **1a**: ¹H NMR (600 MHz, D₂O) δ 1.61 (ddd, 1H, *J* = 12.3 Hz, 12.3 Hz, 9.1 Hz), 2.19–2.28 (m, 2H), 2.73 (dd, 1H, *J* = 15.2 Hz, 2.4 Hz), 3.11 (dd, 1H, *J* = 15.3 Hz, 4.7 Hz), 3.87 (ddd, 1H, *J* = 6.8 Hz, 4.7 Hz, 2.1 Hz), 3.94 (dd, 1H, *J* = 6.2 Hz, 4.7 Hz), 4.24–4.27 (m, 1H), 4.63–4.68 (m, 1H), 5.86 (d, 1H, *J* = 7.9 Hz), 7.66 (d, 1H, *J* = 7.9 Hz); ¹³C NMR (150 MHz,

D₂O) δ 26.0, 40.1, 45.9, 49.6, 55.4, 71.2, 73.4, 101.9, 144.4, 152.3, 166.3, 171.9; HRMS (FAB) m/z [M+H]⁺: calcd for C₁₂H₁₆N₃O₅⁺, 282.1090; found, 282.1081. Compound **1b**: ¹H NMR (600 MHz, D₂O) δ 1.95–2.01 (m, 1H), 2.19–2.26 (m, 2H), 2.76 (dd, 1H, J = 15.2 Hz, 2.3 Hz), 3.13 (dd, 1H, J = 15.3 Hz, 4.7 Hz), 3.98 (ddd, 1H, J = 6.5 Hz, 5.0 Hz, 2.4 Hz), 4.24–4.27 (m, 1H), 4.29 (dd, 1H, J = 7.3 Hz, 4.4 Hz), 4.99–5.04 (m, 1H), 5.82 (d, 1H, J = 8.2 Hz), 7.90 (d, 1H, J = 7.9 Hz); ¹³C NMR (150 MHz, D₂O) δ 28.5, 40.8, 42.4, 48.1, 55.4, 71.2, 72.1, 100.6, 146.1, 152.7, 166.3, 171.9; HRMS (FAB) m/z [M+H]⁺: calcd for C₁₂H₁₆N₃O₅⁺, 282.1090; found, 282.1081.

(±)-(S*)-3-amino-3-((1R*,2R*,3S*,4R*)-4-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,3-dihydroxycyclopentyl) propanoic acid 2a and (±)-(S*)-3-amino-3-((1R*,2S*,3R*,4R*)-4-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,3-dihydroxycyclopentyl)propanoic acid 2b

A water solution (0.36 mL) of a 1:8 ratio of **1a:1b** (10 mg, 0.036 mmol) was treated with 2M NaOH (0.089 mL, 0.18 mmol) and was stirred for 18 h at rt. The reaction mixture was adjusted to pH 7 with 1M HCl. The neutralized reaction mixture was concentrated to solids under reduced pressure. The crude material was adsorbed on Sephadex LH20 and eluted with MeOH to afford a 1:6 ratio of **2a:2b** as white solids (10.6 mg, 94%). Compound **2a**: ¹H NMR (600 MHz, D₂O) δ 1.67–1.72 (m, 1H), 2.22–2.29 (m, 2H), 2.50 (dd, 1H, J = 17.5 Hz, 9.5 Hz), 2.75 (dd, 1H, J = 17.5 Hz, 4.0 Hz), 3.58 (ddd, 1H, J = 9.2 Hz, 8.6 Hz, 3.4 Hz), 3.91–3.94 (m, 1H), 4.06–4.08 (m, 1H), 4.56–4.62 (m, 1H), 5.86 (d, 1H, J = 8.0 Hz), 7.67 (d, 1H, J = 8.0 Hz); ¹³C NMR (125 MHz, D₂O) δ 27.0, 37.0, 40.3, 45.3, 51.5, 70.5, 72.8, 102.0, 144.5, 152.5, 166.5, 177.9; HRMS (ESI) m/z [M+H]⁺: calcd for C₁₂H₁₈N₃O₆⁺, 300.1196; found, 300.1190. HRMS (ESI) m/z [M+Na]⁺: calcd for C₁₂H₁₇N₃NaO₆, 322.1015; found, 322.1010. Compound **2b**: ¹H NMR (600 MHz, D₂O) δ 1.97 (ddd, 1H, J = 12.6 Hz, 12.6 Hz, 10.0 Hz), 2.21–2.26 (m, 1H), 2.33 (ddd, 1H, J = 12.6 Hz, 8.2 Hz, 7.0 Hz), 2.50 (dd, 1H, J = 16.7 Hz, 8.5 Hz), 2.66 (dd, 1H, J = 16.4 Hz, 4.7 Hz), 3.72 (ddd, 1H, J = 10.8 Hz, 7.3 Hz, 4.7 Hz), 4.29–4.32 (m, 2H), 5.08 (ddd, 1H, J = 10.0 Hz, 8.2 Hz, 8.2 Hz), 5.84 (d, 1H, J = 7.9 Hz), 7.92 (d, 1H, J = 7.9 Hz); ¹³C NMR (150 MHz, D₂O) δ 29.0, 38.6, 40.7, 49.2, 54.8, 70.9, 71.6, 100.9, 146.0, 156.9, 166.3, 178.1; HRMS (ESI) m/z [M+H]⁺: calcd for C₁₂H₁₈N₃O₆⁺, 300.1196; found, 300.1190. HRMS (ESI) m/z [M+Na]⁺: calcd for C₁₂H₁₇N₃NaO₆, 322.1015; found, 322.1010.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We would like to thank Dr. Jed Fisher for helpful discussions, Dr. Bill Boggess and Nonka Sevova for mass spectroscopic analyses and Dr. Jaroslav Zajicek for NMR assistance. We acknowledge The University of Notre Dame and NIH (GM068012) for support of this work.

References

1. For a review of synthetic methods, see: Zhang D, Miller MJ. *Curr. Pharm. Design* 1999;5:73–99.99
2. Chitin synthase as an antifungal target, see: Ruiz-Herrera J, San-Blas G. *Curr. Drug Targets- Infectious Disorders* 2003;3:77–91.91 (b) Behr J-B. *Curr. Med. Chem.- Anti-Infective Agents* 2003;2:173–189.189
3. Ruiz-Herrera, J. *Fungal Cell Wall: Structure, Synthesis and Assembly*. Boca Raton: CRC Press; 1992.
4. Gooday, GW. *The Biochemistry of Cell Walls and Membranes in Fungi*. Goosey, M.; Kuhn, P.; Trinci, APJ., editors. Springer-Verlag: Berlin; 1989. p. 61-76.
5. Naider, F.; Becker, JM. *Current Topics in Medical Mycology II*. McGinnis, MM., editor. Springer: Berlin; 1987. p. 170-198.

6. Shenbagamurthi P, Smith HA, Becker JM, Naider F. J. Med. Chem 1986;29:802–809. [PubMed: 2939243]
7. Emmer G, Ryder NS, Grassberger MA. J. Med. Chem 1985;28:278–281. [PubMed: 3156247]
8. Azuma T, Isono K, Crain PF, McCloskey JA. J. Chem. Soc., Chem. Comm 1977;5:159–160.
9. (a) Krainer E, Becker JM, Naider F. J. Med. Chem 1991;34:174–180. [PubMed: 1992114] (b) Naider F, Shenbagamurthi P, Steinfeld AS, Smith HA, Boney C, Becker JM. Antimicrob. Agents Chemother 1983;24:787–796. [PubMed: 6362556]
10. (a) Casu F, Chiacchio MA, Romeo R, Gumina G. Curr. Org. Chem 2007;11:999–1016. (b) Jeong LS, Lee JA. Antivir. Chem. Chemoth 2004;15:235–250. (c) Rodriguez JB, Comin MJ. Mini-Rev. Med. Chem 2003;3:95–114. [PubMed: 12570843] (d) Marquez VE, Lim MI. Med. Res. Rev 1986;6:1–40. [PubMed: 3512934]
11. (a) Li F, Brogan JB, Gage JL, Zhang D, Miller MJ. J. Org. Chem 2004;69:4538–4540. [PubMed: 15202916] (b) Zhang D, Miller MJ. J. Org. Chem 1998;63:755–759. [PubMed: 11672070] (c) Ward SE, Holmes AB, Ward SE, McCague R. Chem. Comm 1997;21:2085–2086. (d) Aggarwal VK, Monteiro N. Org. Biomol. Chem 1997;17:2531–2537. (e) Aggarwal VK, Monteiro N, Tarver GJ, Lindell SD. J. Org. Chem 1996;61:1192–1193.
12. Cesario C, Miller MJ. Org. Lett 2009;11:1293–1295. [PubMed: 19216521]
13. Isono K, Asahi K, Suzuki S. J. Am. Chem Soc 1969;91:7490–7505. [PubMed: 5358618]
14. Hori M, Kakiki K, Misato T. Agric. Biol. Chem 1974;38:699–705.
15. Cesario C, Tardibono LP, Miller MJ. J. Org. Chem 2009;74:448–451. [PubMed: 19053586]
16. For a detailed preparation of acyl isocyanate **6**, refer to experimental section or see: Santana L, Teijeira M, Uriarte E. J. Heterocyclic Chem 1999;36:293–295.
17. (a) Woulfe SR, Miller MJ. J. Org. Chem 1986;51:3133–3139. (b) Woulfe SR, Iwagami H, Miller MJ. Tetrahedron Lett 1985;3:3891–3894.
18. Shah NV, Cama LD. Heterocycles 1987;25:221–227.
19. For preparation of *N*-methylthiophthalimide **9**, refer to Supporting Information.
20. Recently, a class of *N*-alkylthio β -lactams demonstrated anti-cancer activity. For recent examples of *N*-alkylthio β -lactams as anti-cancer agents, see: (a) Kuhn DJ, Wang Y, Minic V, Coates C, Reddy, Kumar GS, Daniel KG, Shim J-Y, Chen D, Landis-Piwowar KR, Miller FR, Turos E, Dou QP. Front. Biosci 2005;10:1183–1190. [PubMed: 15769617] (b) Kazi A, Hill R, Long TE, Kuhn DJ, Turos E, Dou QP. Biochem. Pharmacol 2004;67:365–374. [PubMed: 14698048] (c) Smith DM, Aslamuzzaman K, Smith L, Long TE, Heldreth B, Turos E, Dou QP. Mol. Pharmacol 2002;61:1348–1358.
21. When *J* values from the allylic methine protons and respective *trans*-methylene proton of 1,4-*syn* cyclopentenones are > 5.5 Hz, OsO₄-mediated dihydroxylation occurs from opposite face of the allylic methine protons and *syn*-tetrasubstituted cyclopentanones result. For compound **8**, *J* = 6.8 Hz and all *syn* diastereomer **1b** was obtained as the major product after dihydroxylation. For an explanation of how 1,4-disubstituted cyclopentene conformations are determined from coupling constants, see: Katagiri N, Ito Y, Kitano K, Toyota A, Kaneko C. Chem. Pharm. Bull 1994;42:2653–2663.
22. Woodward RB, Brucher FV Jr. J. Am. Chem. Soc 1958;80:209–211.
23. The Woodward-Prevost reaction has been described as a complementary method to OsO₄ dihydroxylation, see: Corey EJ, Das J. Tetrahedron Lett 1982;23:4217–4220.
24. Barkley JV, Dhanda A, Knutsen LJS, Nielsen MB, Roberts SM, Varley DR. Chem. Commun 1998;10:1117–1118.

Scheme 1.
Initial Synthetic Route to Uracil **8**.

Scheme 2.
Revised Synthetic Route to Uracil **8**.

Scheme 3.
Syntheses of Uracil Polyoxin C Analogs

X = O, Uracil Polyoxin C
X = CH₂, Carbocyclic Uracil
Polyoxin C

Polyoxin I

Carbocyclic Uracil
Polyoxin C Analog
(5'-epimer)
1a

Carbocyclic Uracil
Polyoxin C Analog
(5'-epimer)
2a

Chart 1.
Representative Polyoxins and Related Carbocyclic Analogs.